慢性髓性白血病患者对酪氨酸激酶抑制剂治疗的依从性。
Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
机构信息
Department of Leukemia, Division of Cancer Medicine, The University of Texas: MD Anderson Cancer Center, Houston, USA.
出版信息
Am J Hematol. 2012 Jul;87(7):687-91. doi: 10.1002/ajh.23180. Epub 2012 Mar 31.
Abstract
Dramatically improved survival associated with tyrosine kinase inhibitor (TKI) therapy has transformed the disease model for chronic myeloid leukemia (CML) to one of long-term management, but treatment success is challenged with poor medication adherence. Many risk factors associated with poor adherence can be ameliorated by close monitoring, dose modification, and supportive care. Controlling risk factors for poor adherence in combination with patient education that includes direct communication between the health care team and the patient are essential components for maximizing the benefits of TKI therapy.
摘要
酪氨酸激酶抑制剂 (TKI) 治疗显著改善了慢性髓性白血病 (CML) 的生存预后，使该疾病的治疗模式转变为长期管理模式，但治疗的成功受到药物依从性差的挑战。许多与药物依从性差相关的风险因素可以通过密切监测、剂量调整和支持性护理来改善。控制药物依从性差的风险因素，并结合包括医疗团队与患者之间直接沟通的患者教育，是最大限度发挥 TKI 治疗益处的重要组成部分。
相似文献
1
Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia.慢性髓性白血病患者对酪氨酸激酶抑制剂治疗的依从性。
Am J Hematol. 2012 Jul;87(7):687-91. doi: 10.1002/ajh.23180. Epub 2012 Mar 31.
2
Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia.慢性髓性白血病患者酪氨酸激酶抑制剂的费用分担与依从性。
J Clin Oncol. 2014 Feb 1;32(4):306-11. doi: 10.1200/JCO.2013.52.9123. Epub 2013 Dec 23.
3
Imatinib mesylate in chronic myeloid leukemia.甲磺酸伊马替尼治疗慢性粒细胞白血病
Curr Stem Cell Res Ther. 2007 Sep;2(3):249-51. doi: 10.2174/157488807781696276.
4
Initial treatment for patients with CML.CML 患者的初始治疗。
Hematology Am Soc Hematol Educ Program. 2009:453-60. doi: 10.1182/asheducation-2009.1.453.
5
The efficacy of generic formulations of imatinib mesylate in the treatment of chronic myeloid leukemia.甲磺酸伊马替尼仿制药制剂治疗慢性髓性白血病的疗效。
Leuk Lymphoma. 2014 Dec;55(12):2935-7. doi: 10.3109/10428194.2014.905774. Epub 2014 May 6.
6
[Management of chronic myeloid leukemia].[慢性髓性白血病的管理]
Rinsho Ketsueki. 2008 Oct;49(10):1401-10.
7
Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective study.伊马替尼治疗高龄慢性髓性白血病慢性期患者：一项回顾性研究。
Drugs Aging. 2013 Aug;30(8):629-37. doi: 10.1007/s40266-013-0088-6.
8
[Resistance against tyrosine kinase inhibitors in the treatment of GIST. New therapeutic possibilities appear].[胃肠道间质瘤治疗中对酪氨酸激酶抑制剂的耐药性。新的治疗可能性出现]
Lakartidningen. 2009;106(50-51):3424-9.
9
Cost-effectiveness of dasatinib and nilotinib for imatinib-resistant or -intolerant chronic phase chronic myeloid leukemia.达沙替尼和尼洛替尼治疗伊马替尼耐药或不耐受的慢性期慢性髓性白血病的成本效益分析。
Value Health. 2011 Dec;14(8):1057-67. doi: 10.1016/j.jval.2011.07.006. Epub 2011 Oct 12.
10
Targeted cancer therapy: from bench to bedside to patient.靶向癌症治疗：从实验室到临床再到患者。
J Clin Oncol. 2014 Feb 1;32(4):268-70. doi: 10.1200/JCO.2013.53.8413. Epub 2013 Dec 23.
引用本文的文献
1
Using Early Biomarker Change and Treatment Adherence to Predict Risk of Relapse Among Patients With Chronic Myeloid Leukemia Who Are in Remission.利用早期生物标志物变化和治疗依从性预测慢性髓性白血病缓解期患者的复发风险。
JCO Clin Cancer Inform. 2025 Jul;9:e2500003. doi: 10.1200/CCI-25-00003. Epub 2025 Jul 7.
2
Identifying Key Factors Influencing Non-adherence to Imatinib Therapy in Patients With Chronic Myeloid Leukemia.识别影响慢性髓性白血病患者伊马替尼治疗依从性的关键因素。
Cureus. 2025 Feb 28;17(2):e79831. doi: 10.7759/cureus.79831. eCollection 2025 Feb.
3
Digital Solution to Support Medication Adherence and Self-Management in Patients with Cancer (SAMSON): Pilot Randomized Controlled Trial.支持癌症患者药物依从性和自我管理的数字解决方案（SAMSON）：试点随机对照试验
JMIR Form Res. 2025 Feb 19;9:e65302. doi: 10.2196/65302.
4
Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in South Africa.南非慢性粒细胞白血病酪氨酸激酶抑制剂治疗策略的成本效益
Front Pharmacol. 2025 Jan 7;15:1511603. doi: 10.3389/fphar.2024.1511603. eCollection 2024.
5
Body mass index affects imatinib exposure: Real-world evidence from TDM with adaptive dosing.体重指数影响伊马替尼的药物暴露：来自治疗药物监测与适应性给药的真实世界证据。
Fundam Clin Pharmacol. 2025 Feb;39(1):e13049. doi: 10.1111/fcp.13049.
6
Playing Hide-and-Seek with Tyrosine Kinase Inhibitors: Can We Overcome Administration Challenges?与酪氨酸激酶抑制剂玩捉迷藏：我们能否克服给药挑战？
AAPS J. 2024 Jun 11;26(4):66. doi: 10.1208/s12248-024-00939-1.
7
Maximizing the Value of Chronic Myeloid Leukemia Management Using Tyrosine Kinase Inhibitors in the USA: Potential Determinants and Consequences of Healthcare Resource Utilization and Costs, with Proposed Optimization Approaches.优化美国慢性髓性白血病管理中使用酪氨酸激酶抑制剂的价值：医疗资源利用和成本的潜在决定因素和后果，以及提出的优化方法。
Clin Drug Investig. 2024 Feb;44(2):91-108. doi: 10.1007/s40261-023-01329-9. Epub 2024 Jan 5.
8
Management of chronic myeloid leukemia in 2023 - common ground and common sense.2023 年慢性髓性白血病的管理——共识与常理。
Blood Cancer J. 2023 Apr 24;13(1):58. doi: 10.1038/s41408-023-00823-9.
9
Personality traits favourable for non-adherence to treatment in patients with chronic myeloid leukaemia: role of type A and D personality.慢性髓性白血病患者中不利于治疗依从性的人格特质：A型和D型人格的作用。
Biopsychosoc Med. 2023 Jan 19;17(1):1. doi: 10.1186/s13030-023-00261-w.
10
Relevance of Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors in Routine Clinical Practice: A Pilot Study.酪氨酸激酶抑制剂治疗药物监测在常规临床实践中的相关性：一项初步研究。
Pharmaceutics. 2022 Jun 8;14(6):1216. doi: 10.3390/pharmaceutics14061216.
本文引用的文献
1
Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia.对于慢性期慢性髓性白血病患者，不依从伊马替尼治疗会对无事件生存产生不良影响。
Am J Hematol. 2011 Jun;86(6):471-4. doi: 10.1002/ajh.22019. Epub 2011 Apr 27.
2
Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy.依从性差是慢性髓性白血病患者长期治疗中导致 CCyR 丧失和伊马替尼治疗失败的主要原因。
Blood. 2011 Apr 7;117(14):3733-6. doi: 10.1182/blood-2010-10-309807. Epub 2011 Feb 23.
3
Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed.探讨慢性髓性白血病患者未按规定服用口服抗癌药物伊马替尼的原因。
Leuk Res. 2011 May;35(5):626-30. doi: 10.1016/j.leukres.2010.10.017. Epub 2010 Nov 20.
4
Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia.回顾性真实世界研究比较尼洛替尼和达沙替尼治疗慢性髓性白血病的就诊次数、费用和依从性。
Curr Med Res Opin. 2010 Dec;26(12):2861-9. doi: 10.1185/03007995.2010.533648. Epub 2010 Nov 9.
5
Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.对于在伊马替尼治疗下达到完全细胞遗传学缓解的慢性髓性白血病患者，其分子学反应的取得取决于是否有较好的依从性。
J Clin Oncol. 2010 May 10;28(14):2381-8. doi: 10.1200/JCO.2009.26.3087. Epub 2010 Apr 12.
6
Potential Clinical and Economic Impact of Nonadherence with Osteoporosis Medications.骨质疏松症药物治疗依从性不佳的潜在临床和经济影响。
Calcif Tissue Int. 2010 Mar;86(3):202-210. doi: 10.1007/s00223-009-9329-4. Epub 2010 Jan 10.
7
Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients.与慢性髓性白血病患者不依从伊马替尼治疗相关的医疗资源利用和成本。
Curr Med Res Opin. 2010 Jan;26(1):61-9. doi: 10.1185/03007990903396469.
8
Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective.造血细胞移植受者感染并发症预防指南：全球视角
Biol Blood Marrow Transplant. 2009 Oct;15(10):1143-238. doi: 10.1016/j.bbmt.2009.06.019.
9
Practical considerations for the management of patients in the tyrosine kinase inhibitor era.酪氨酸激酶抑制剂时代患者管理的实际考量
Semin Hematol. 2009 Apr;46(2 Suppl 3):S16-21. doi: 10.1053/j.seminhematol.2009.01.010.
10
Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study.慢性髓性白血病患者伊马替尼治疗不依从的患病率、决定因素及结局：ADAGIO研究
Blood. 2009 May 28;113(22):5401-11. doi: 10.1182/blood-2008-12-196543. Epub 2009 Apr 6.
Zotero 插件